Royce & Associates LP Takes Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Royce & Associates LP acquired a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 37,225 shares of the medical equipment provider's stock, valued at approximately $3,330,000. Royce & Associates LP owned approximately 0.05% of Lantheus as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of LNTH. Wilmington Savings Fund Society FSB bought a new position in shares of Lantheus during the third quarter valued at approximately $25,000. Kestra Investment Management LLC bought a new position in shares of Lantheus during the fourth quarter valued at approximately $27,000. UMB Bank n.a. grew its holdings in shares of Lantheus by 31.5% during the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after purchasing an additional 134 shares during the last quarter. World Investment Advisors LLC bought a new position in shares of Lantheus during the third quarter valued at approximately $60,000. Finally, Parkside Financial Bank & Trust grew its holdings in shares of Lantheus by 49.4% during the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock valued at $76,000 after purchasing an additional 280 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Insider Buying and Selling at Lantheus

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. This trade represents a 8.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director James H. Thrall sold 1,000 shares of the stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now owns 33,207 shares of the company's stock, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 64,109 shares of company stock valued at $6,110,806. 1.50% of the stock is owned by corporate insiders.

Remove Ads

Analyst Upgrades and Downgrades

Several research firms have recently commented on LNTH. Truist Financial upped their target price on Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a report on Thursday, February 27th. JMP Securities reaffirmed a "market outperform" rating and set a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. B. Riley lowered their target price on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a report on Friday. Finally, The Goldman Sachs Group initiated coverage on Lantheus in a report on Wednesday, December 18th. They issued a "buy" rating and a $143.00 price objective for the company. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $129.43.

Lantheus Price Performance

LNTH stock traded down $1.14 on Friday, reaching $97.71. The company's stock had a trading volume of 1,069,481 shares, compared to its average volume of 936,960. Lantheus Holdings, Inc. has a 52 week low of $57.92 and a 52 week high of $126.89. The company has a market capitalization of $6.69 billion, a P/E ratio of 16.26 and a beta of 0.38. The firm has a fifty day moving average of $92.67 and a two-hundred day moving average of $96.58.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). The firm had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. As a group, equities analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.